Novo Nordisk inks multimillion-dollar deal with Ventus Therapeutics
![Photo: Stine Tidsvilde](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14354076.ece/ALTERNATES/schema-16_9/doc7mj0bbnud1e1kklpk1g1.jpg)
Danish pharmaceutical giant Novo Nordisk has signed a development and license agreement with Ventus Therapeutics, a US-based biotech focused on using small molecules to treat challenging targets, the latter firm announces in a press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Pfizer drops phase II-ready NASH candidate
For subscribers